Shanghai Enkai Cell Technology Co.
Latest round
- Series A
Last raised
- Jul 2025
Total raised
- $29M
Investors
- 11
About Shanghai Enkai Cell Technology Co.
, Ltd is a cellular drug discovery and development company. The founder of this company, Zhigang Tian, is the founding director of the Institute of Immunology at the University of Science and Technology of China (USTC) and director of the Key Laboratory of Innate Immunity and Chronic Diseases at the Chinese Academy of Sciences (CAS). The company’s main business is the R&D and production of innovative cell drugs based on NK cells. The company’s self-developed products include a series of original intelligent NK cell products under the ABCDE-NK® strategic platform, such as technologies and products in four major categories and twelve series. Its products are used in the field of treating major clinical diseases., Ltd generates revenue by providing NK cell-based immunotherapy solutions and related cell products.
Who invested in Shanghai Enkai Cell Technology Co.
11 investors across 3 rounds
See all investors in Shanghai Enkai Cell Technology Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Shanghai Enkai Cell Technology Co.
Who invested in Shanghai Enkai Cell Technology Co.?
Shanghai Enkai Cell Technology Co. has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Shanghai Enkai Cell Technology Co. raised?
Shanghai Enkai Cell Technology Co. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Shanghai Enkai Cell Technology Co. last raise money?
Shanghai Enkai Cell Technology Co.'s most recent round on record is a Series A, in Jul 2025.
What does Shanghai Enkai Cell Technology Co. do?
, Ltd is a cellular drug discovery and development company.
Where is Shanghai Enkai Cell Technology Co. headquartered?
Shanghai Enkai Cell Technology Co. is headquartered in Shanghai, China.
Which VCs invest in companies like Shanghai Enkai Cell Technology Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Shanghai Enkai Cell Technology Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Shanghai Enkai Cell Technology Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.